Hansa Biopharma Achieves Key Milestone in Imlifidase Clinical Trial for Guillain-Barré Syndrome
Hansa Biopharma (Nasdaq Stockholm: HNSA), a pioneer in developing enzyme technology for the treatment of rare immunological disorders, is thrilled to report the successful completion of enrollment in its innovative…